28 results
8-K
EX-99.1
CDTX
Cidara Therapeutics Inc
6 Sep 23
Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
8:05am
ongoing development activities by Janssen as provided in the Janssen Collaboration Agreement. The complete CD388 Phase 2a data package is currently
8-K
EX-99.1
CDTX
Cidara Therapeutics Inc
3 Aug 23
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:03pm
90 days after Cidara delivers the complete CD388 Phase 2a data package to Janssen, Janssen is required to notify Cidara whether it will proceed … and whether Janssen will elect to continue clinical development of CD388 following delivery of the Phase 2a data package, whether REZZAYO
8-K
EX-99.1
dxk by044o
7 Mar 22
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
5:15pm
8-K
EX-99.1
ekscql087b0purq3d
14 Dec 21
Regulation FD Disclosure
7:05am
8-K
EX-99.1
9twu9 22s
21 Sep 21
Other Events
4:00pm
8-K
i2lbe318s30 cuzx5
5 Apr 21
Entry into a Material Definitive Agreement
7:07am